Cellular Biomedicine Group certified to ISO 9001:2008 and ISO-14644

Published: 19-Feb-2013
Regulatory Pharmaceutical

Only cell therapy company in China to be awarded ISO 9001:2008 by SGS


Cellular Biomedicine Group (CBMG), a developer of cell therapies for the treatment of certain degenerative diseases, has achieved both ISO 9001:2008 certification and ISO-14644 cleanroom certification.

Shanghai, China-based Cellular Biomedicine Group has been accredited the ISO 9001:2008 certification by inspection, verification, testing and certification company SGS. The American National Accreditation Bureau (ANAB) issued the certificate. ISO 9001:2008 addresses the requirements for implementing an efficient quality management system.

In addition, since 2012 CBMG has maintained an ISO-14644 cleanroom certification from ENV Services. ENV is an ISO-accredited, US-based testing and certification company, certified in Cleanroom Performance Testing according to the NEBB (National Environmental Balancing Bureau).

“We are extremely proud to obtain ISO 9001:2008 and ENV certification, which are important milestones in the development of our company,” said CBMG President Dr William Cao. “It is a significant achievement that demonstrates the commitment to a level of excellence upon which our partners can depend. We look forward to announcing additional milestones as we continue to execute on our growth strategy.”

  • Companies:
  • Cellular Biomedicine Group CBMG
See more

You may also like

Manufacturing

CBMG accelerates cell therapy manufacturing

Read more
GE Healthcare’s new start-to-finish solution — FlexFactory — for cell therapy installation will provide Cellular Biomedicine Group (CBMG) with scalable, fully-equipped cell therapy manufacturing capabilities, training and services

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

CBMG accelerates cell therapy manufacturing

GE Healthcare’s new start-to-finish solution — FlexFactory — for cell therapy installation will provide Cellular Biomedicine Group (CBMG) with scalable, fully-equipped cell therapy manufacturing capabilities, training and services
Research & Development

CBMG and GE Healthcare China establish joint tech lab

Research and development collaboration to take place in Cellular Biomedicine GMP facilities
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Subscribe now